Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles

At first glance, I saw their acronym TMZ and thought trastuzumab (Herceptin), sometimes abbreviated TZM. But in this paper they are using a chemo agent temozolomide (TMZ). Many of the BiOasis followers are also quite familiar with one or two Canadian BET bromodomain inhibition companies. Interesting that in this study they are combining TMZ with the pan-BET inhibitor JQ1 into a nanoparticle functionalized with transferrin ligand to enable crossing the BBB via transferrin receptor. Interesting approach. I haven't read carefully enought to assess how efficient their delivery across the BBB was. From what I understand, the transferrin receptor antibody approaches were getting around 1% transport across the BBB. But this alternative approach is attaching the transferrin ligand to the nanoparticle. So slightly different.